In recent years, quinoline-based fibroblast activation protein (FAP) inhibitors (FAPI) have
shown promising results in the diagnosis of cancer and several other diseases, making them …

Fibroblast activation protein (FAP) is a type II membrane-bound glycoprotein which is
overexpressed in cancer-associated fibroblasts and activated fibroblasts at wound …

Breast cancer prognosis is steadily improving due to early detection of primary cancer in
screening programs and revolutionizing treatment development. In the metastatic setting …

Purpose The study aimed to provide a comprehensive bibliometric overview of the current
scientific publications on fibroblast activation protein inhibitor (FAPI) positron emission …

The identification of contributing factors leading to the development of Colorectal Cancer
(CRC), as the third fatal malignancy, is crucial. Today, the tumor microenvironment has been …

A portion of gastric cancer patients with negative lymph node metastasis at an early stage
eventually die from tumor recurrence or advanced metastasis. Occult lymph node metastasis …

Radiolabelled fibroblast activation protein inhibitors (FAPI) are emerging as promising
radiopharmaceuticals for positron emission tomography (PET)[1, 2]. FAPI are molecules …

Various papers have introduced the use of positron emission tomography (PET) with [68Ga]
Ga-radiolabeled fibroblast-activation protein inhibitor (FAPi) radiopharmaceuticals in …

Fibroblast activation protein (FAP) is an emerging target for cancer diagnosis. Different types
of FAP inhibitor (FAPI)-based radiotracers have been developed and applied for tumor …

Positron emission tomography/computed tomography (PET/CT) is a hybrid imaging modality
that has recently experienced a wide increase in its use and applications. The most common …